Adjuvant Ribociclib Plus Endocrine Therapy in Patients With HR+/HER2− Early Breast Cancer: Phase III Results

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the NATALEE study, which evaluated adjuvant ribociclib + estrogen therapy (ET) in patients with stage II or III HR+/HER2− early breast cancer (EBC) at risk for recurrence, including those with no nodal involvement (N0). Ribociclib added to standard-of-care ET demonstrated a statistically significant, clinically meaningful improvement in iDFS with a well-tolerated safety profile. The NATALEE results support ribociclib + ET as the treatment of choice in a broad population of patients with stage II or III HR+/HER2− EBC, including those with N0 disease (Abstract LBA500).